17-4739335-C-T
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_001386809.1(CXCL16):c.5G>A(p.Gly2Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00128 in 1,613,364 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/18 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
NM_001386809.1 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000611 AC: 93AN: 152250Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.000659 AC: 162AN: 245968Hom.: 0 AF XY: 0.000628 AC XY: 84AN XY: 133824
GnomAD4 exome AF: 0.00135 AC: 1971AN: 1460996Hom.: 1 Cov.: 33 AF XY: 0.00126 AC XY: 914AN XY: 726792
GnomAD4 genome AF: 0.000610 AC: 93AN: 152368Hom.: 0 Cov.: 31 AF XY: 0.000550 AC XY: 41AN XY: 74508
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 15, 2021 | The c.62G>A (p.G21E) alteration is located in exon 1 (coding exon 1) of the CXCL16 gene. This alteration results from a G to A substitution at nucleotide position 62, causing the glycine (G) at amino acid position 21 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at